We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
ARS Pharmaceuticals Inc | NASDAQ:SPRY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.11% | 8.97 | 8.97 | 8.99 | 9.16 | 8.83 | 9.15 | 168,015 | 20:03:19 |
The event will include presentations by members of the ARS management team and by two distinguished allergists:
A live question and answer session will follow the formal presentations.
The neffy Investor Day webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.
ARS Media Contact:Laura O’NeillLaura.oneill@finnpartners.com
ARS Pharma Investor Contact:Justin ChakmaARS Pharmaceuticalsjustinc@ars-pharma.com
1 Year ARS Pharmaceuticals Chart |
1 Month ARS Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions